ArticleBiotechnology and bioengineering2022
Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor-binding domain in engineered Komagataella phaffii.
Article in Biotechnology and bioengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Systematic perturbation of cultures of K. phaffii by carbon co-feeding show gene signatures associated with production of recombinant proteins.Microbial cell factories · 2026Article
- Balancing Doses of EL222 and Light Improves Optogenetic Induction of Protein Production in Komagataella phaffii.Biotechnology and bioengineering · 2025Article
- Chances and drawbacks of derepressed recombinant enzyme production in continuous cultivations withFrontiers in bioengineering and biotechnology · 2025Article
- Designing strong inducible synthetic promoters in yeasts.Nature communications · 2024Article
- CRISPR-Cas9 knockout screen informs efficient reduction of the Komagataella phaffii secretome.Microbial cell factories · 2024Article
- Unlocking Nature's Toolbox: glutamate-inducible recombinant protein production from the Komagatella phaffii PEPCK promoter.Microbial cell factories · 2024Article
- Identification of a novel growth-associated promoter for biphasic expression of heterogenous proteins inApplied and environmental microbiology · 2024Article
- Article
- Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.Vaccine · 2023Article
- Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice.NPJ vaccines · 2023Article
- Article
- Enabling growth-decoupledFrontiers in bioengineering and biotechnology · 2023Article
- Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with AldydrogelVaccines · 2022Article
- Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.Human vaccines & immunotherapeutics · 2022Article
- Steric accessibility of the N-terminus improves the titer and quality of recombinant proteins secreted from Komagataella phaffii.Microbial cell factories · 2022Article
- RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.mSphere · 2022Article
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.Science advances · 2022Article
- Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor-binding domain in engineered Komagataella phaffii.Biotechnology and bioengineering · 2022Article
- Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.NPJ vaccines · 2021Review
- A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.bioRxiv : the preprint server for biology · 2021Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
Prevention of COVID-19 on a global scale will require the continued development of high-volume, low-cost platforms for the manufacturing of vaccines to supply ongoing demand. Vaccine candidates based on recombinant protein subunits remain important because they can be manufactured at low costs in existing large-scale production facilities that use microbial hosts like Komagataella phaffii (Pichia pastoris). Here, we report an improved and scalable manufacturing approach for the SARS-CoV-2 spike protein receptor-binding domain (RBD); this protein is a key antigen for several reported vaccine candidates. We genetically engineered a manufacturing strain of K. phaffii to obviate the requirement for methanol induction of the recombinant gene. Methanol-free production improved the secreted titer of the RBD protein by >5X by alleviating protein folding stress. Removal of methanol from the production process enabled to scale up to a 1200 L pre-existing production facility. This engineered strain is now used to produce an RBD-based vaccine antigen that is currently in clinical trials and could be used to produce other variants of RBD as needed for future vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.